{
    "Trade/Device Name(s)": [
        "ADVIA 1650 Chemistry Glucose Hexokinase_3 (GLUH_3) reagent",
        "ADVIA Chemistry Glucose Hexokinase (GLUH_3) Reagent"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K101854",
    "Predicate Device Reference 510(k) Number(s)": [
        "K042015"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFR"
    ],
    "Summary Letter Date": "February 23, 2011",
    "Summary Letter Received Date": "February 24, 2011",
    "Submission Date": "July 26, 2010",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine",
        "Cerebrospinal fluid"
    ],
    "Specimen Container(s)": [
        "Li Heparin tube",
        "K EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA 1650 Chemistry system"
    ],
    "Method(s)/Technology(ies)": [
        "Hexokinase method",
        "Absorbance measurement"
    ],
    "Methodologies": [
        "Enzyme-based quantitation"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA 1650 Chemistry Glucose Hexokinase_3 reagent for quantitative determination of glucose in multiple specimen types using hexokinase method",
    "Indications for Use Summary": "For in vitro diagnostic quantitative determination of glucose in human serum, plasma, urine and CSF to aid diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal and idiopathic hypoglycemia, and insulin overdose",
    "fda_folder": "Clinical Chemistry"
}